Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
10.1038/s41584-020-0441-1 · 2020
Patient and provider barriers to effective management of gout in general practice: a qualitative study.
10.1136/annrheumdis-2011-200801 · 2012
The prevalence of gout in mainland China from 2000 to 2016: a systematic review and meta-analysis.
10.1007/s10389-017-0812-5 · 2017
Epidemiology and management of gout in Taiwan: a nationwide population study.
10.1186/s13075-015-0522-8 · 2015
Gout.
10.1016/s0140-6736(21)00569-9 · 2021
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
10.3899/jrheum.140588 · 2015
2020 American College of Rheumatology guideline for the management of Gout.
10.1002/art.41247 · 2020
Adherence to gout management recommendations of Chinese patients.
10.1097/md.0000000000008532 · 2017
Medication adherence in gout: a systematic review.
10.1002/acr.22336 · 2014
Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
10.1093/rheumatology/key155 · 2018
Adherence and persistence to urate-lowering therapies in the Irish setting.
10.1007/s10067-014-2823-8 · 2016
Allopurinol adherence in US patients with Gout: analysis of the Medical Expenditure Panel Survey, 2018-2021.
10.1097/rhu.0000000000002177 · 2025
Evaluation of treatment compliance in gout patients: a patient-centered study.
10.55730/1300-0144.5985 · 2025
Adherence to long-term therapies: evidence for action.
10.1016/s1474-5151(03)00091-4 · 2003
The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
10.1007/s00296-017-3746-x · 2017
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
10.1002/art.39254 · 2015
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study.
2003
Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy.
1999
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
10.1186/1471-2474-13-174 · 2012
Development and evaluation of a survey of gout patients concerning their knowledge about gout.
10.1097/rhu.0b013e318228b4e2 · 2011
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
10.1097/00005650-199206000-00002 · 1992
The PHQ-9: validity of a brief depression severity measure.
10.1046/j.1525-1497.2001.016009606.x · 2001
A brief measure for assessing generalized anxiety disorder: the GAD-7.
10.1001/archinte.166.10.1092 · 2006
Allopurinol adherence among patients with gout: an Italian general practice database study.
10.1111/ijcp.12604 · 2015
High rate of adherence to urate-lowering treatment in patients with gout: who’s to blame?
10.1007/s40744-020-00249-w · 2020
Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study.
10.1093/rheumatology/keae514 · 2025
COVID-19 infection and rheumatoid arthritis: faraway, so close!
10.1016/j.autrev.2020.102523 · 2020
Capturing patient-reported outcomes during the COVID-19 pandemic: development of the COVID-19 global rheumatology alliance patient experience survey.
10.1002/acr.24257 · 2020
Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic.
10.1002/acr2.11148 · 2020
